FDA To Review Pfizer’s Abrilada For Humira Interchangeability

Adalimumab Biosimilar Is Set For US Launch In July 2023

 
• By Chloe Kent
  
Signpost two directions
Pfizer is seeking an interchangeable designation for its adalimumab biosimilar • Source: Frannyanne / Alamy Stock Photo

More from Biosimilars

More from Products